Amgen Inc. which can be found using ticker (AMGN) have now 22 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between 301.79 and 174.47 with the average target price sitting at $258.80. Given that the stocks previous close was at $276.12 this indicates there is a potential downside of -6.3%. Also worth taking note is the 50 day moving average now sits at $266.45 while the 200 day moving average is $244.73. The company has a market cap of 145.58B. The stock price for the company is currently 272.16 USD
The potential market cap would be $136,447,037,906 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 18.35, revenue per share of 49.73 and a 8.54% return on assets.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
